1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STAT1 regulates immune-mediated intestinal stem cell proliferation and epithelial regeneration
    Journal Article

    Takashima, S.; Sharma, R.; Chang, W.; Calafiore, M.; Fu, Y. Y.; Jansen, S. A.; Ito, T.; Egorova, A.; Kuttiyara, J.; Arnhold, V.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save
  • New treatments for adult T-cell leukemia/lymphoma
    Review

    Epstein-Peterson, Z. D.; Gurumurthi, A.; Horwitz, S. M.
    Leukemia Research (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: A phase 1, first-in-human trial
    Journal Article

    Ghobadi, A.; Bachanova, V.; Patel, K.; Park, J. H.; Flinn, I.; Riedell, P. A.; Bachier, C.; Diefenbach, C. S.; Wong, C.; Bickers, C.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)
    Editorial

    Schmitz, K. H.; Brown, J. C.; Irwin, M. L.; Robien, K.; Scott, J. M.; Berger, N. A.; Caan, B.; Cercek, A.; Crane, T. E.; Evans, S. R.; more...
    JNCI: Journal of the National Cancer Institute (2025)

    Fulltext@MSK | Save
  • Next-generation sequencing for HLA genotype screening and matching to HLA-restricted therapies
    Research Letter

    Gormally, M. V.; Chen, M. F.; Noronha, A. M.; Panageas, K.; Reynolds, M.; Kohlasch, K.; Novak, B.; Kee-Velez, T.; Clarke, N.; Eubank, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Impact of recent translational and therapeutic developments on clinical course of BCR::ABL1-positive and -negative myeloproliferative neoplasms
    Review

    Mughal, T. I.; Mascarenhas, J.; Rampal, R. K.; Bose, P.; Lion, T.; Ajufo, H.; Yacoub, A.; Meshinchi, S.; Masarova, L.; Mesa, R.; more...
    Hematological Oncology (2025)

    Fulltext@MSK | Save
  • Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: Results of the phase I/II BRUIN trial
    Journal Article

    Shah, N. N.; Wang, M.; Roeker, L. E.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Help or hindrance? Rituximab maintenance and COVID
    Editorial

    Noy, A.
    Haematologica (2025)

    Fulltext@MSK | Save
  • Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: A systematic literature review
    Review

    Marks, D. I.; Cassaday, R. D.; Ribera, J. M.; Schuh, A. C.; Park, J. H.; Chiaretti, S.; Stelljes, M.
    Expert Review of Hematology (2025)

    Fulltext@MSK | Save